DOCSLIB.ORG

Open Innovation and External Sources of Innovation. an Opportunity to Fuel

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Open Innovation and External Sources of Innovation. an Opportunity to Fuel Schuhmacher et al. J Transl Med (2018) 16:119 https://doi.org/10.1186/s12967-018-1499-2 Journal of Translational Medicine REVIEW Open Access Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making? Alexander Schuhmacher1* , Oliver Gassmann2, Nigel McCracken3 and Markus Hinder4 Abstract Historically, research and development (R&D) in the pharmaceutical sector has predominantly been an in-house activity. To enable investments for game changing late-stage assets and to enable better and less costly go/no-go decisions, most companies have employed a fail early paradigm through the implementation of clinical proof-of-con- cept organizations. To fuel their pipelines, some pioneers started to complement their internal R&D eforts through collaborations as early as the 1990s. In recent years, multiple extrinsic and intrinsic factors induced an opening for external sources of innovation and resulted in new models for open innovation, such as open sourcing, crowdsourc- ing, public–private partnerships, innovations centres, and the virtualization of R&D. Three factors seem to determine the breadth and depth regarding how companies approach external innovation: (1) the company’s legacy, (2) the company’s willingness and ability to take risks and (3) the company’s need to control IP and competitors. In addition, these factors often constitute the major hurdles to efectively leveraging external opportunities and assets. Conscious and diferential choices of the R&D and business models for diferent companies and diferent divisions in the same company seem to best allow a company to fully exploit the potential of both internal and external innovations. Keywords: Open innovation, Pharmaceutical industry, Public–private partnerships, Crowdsourcing, Knowledge leverager Background most) decisions that take into account the probability of Traditionally, pharma R&D organizations are fully inte- technical success (PoS), the likelihood of achieving the grated; they are composed of various units with diferent target product profle (TPP) and the resources needed competencies, skills and technologies and have complex to achieve the TPP. Te translation of innovations from interfaces to accomplish the multi-disciplinary tasks research into clinically meaningful therapies for patients required for developing new drugs. Regulatory hurdles, has become the key value generating step in pharmaceu- complex research for new drug targets, or the low pre- tical R&D. Nonetheless, in view of the high complexity dictability of animal models are some examples of why of clinical PoC, the attrition rate in the PoC phase is still the industry is struggling with its R&D input/output- the highest. Tis raises the question regarding whether ratio [1, 2]. Tese internal and external challenges made a decentralized and more open R&D organization that it necessary for companies to improve their R&D efcien- accesses additional competencies, skills and technologies cies, e.g. by outsourcing to reduce overhead costs, by the from external sources could be a measure to increase the installation of proof-of-concept (PoC) organizations or R&D efciency. by enhanced scientifc rigor in data-driven project deci- Generally, a centralized R&D approach is particularly sion-making. Te latter is included today in many (if not favoured and relevant in disease areas that necessitate large and long clinical trials to demonstrate PoC and where deep developmental, regulatory and commer- *Correspondence: alexander.schuhmacher@reutlingen‑university.de 1 Reutlingen University, Alteburgstrasse 150, 72762 Reutlingen, Germany cial expertise is essential. Whenever an R&D activity is Full list of author information is available at the end of the article more singular and autonomous or as soon as less synergy © The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat​iveco​mmons​.org/licen​ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat​iveco​mmons​.org/ publi​cdoma​in/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Schuhmacher et al. J Transl Med (2018) 16:119 Page 2 of 14 within a portfolio of R&D projects exist, a decentralized open source activity in the biomedical environment [17]. R&D may have advantages over a central R&D organiza- In addition, open-access scientifc journals follow the tion since the company has the opportunity to copy the principle of the free distribution of scientifc informa- science-based biotech business model. Hence, pharma tion and knowledge. Other examples that are known are companies have increasingly moved away from internal from non-proft organizations and governments to dis- R&D models towards more open and collaborative R&D cover drugs for neglected diseases in collaboration with models following the paradigm of open innovation [3]. pharma companies [18]: In this vein, they have established specifc collaborations with academic centres of excellence, built innovation • In 1974, the Special Program for Research and Train- centres, made joint ventures with academic institutions ing in Tropical Diseases (TDR, http://www.who.int/ (public–private partnerships, PPP), established precom- tdr/en/) was initiated by the World Health Organi- petitive consortia, or experimented with crowdsourcing zation (WHO) as a global programme of scientifc and virtual R&D [4–7]. Some models even let com- collaboration to combat neglected diseases [18]. Te petitors collaborate and become partners [8]. Currently, programme is hosted at the WHO and funded by many companies have put greater focus on leveraging co-sponsors, governments, foundations and agen- external knowledge, licensing or acquiring drug candi- cies, such as the World Bank, the European Com- dates and changing their R&D models from primarily mission, or the Bill and Melinda Gates Foundation inside-driven concepts to plans that more closely follow [19]. Te African Network for Drugs and Diagnostics the open innovation paradigm [4]. As a consequence, Innovation (ANDI) is a programme of the TDR that the proportion of externally sourced R&D assets has started in 2008 under the governance of the United increased in the past years [9]. Tis rise in externally Nations Economic Commission for Africa (UNECA). sourced innovation coincided with several cases of major It focuses on the specifc health needs in Africa and downsizing in R&D departments, with Merck, AstraZen- aims at promoting and supporting pharmaceutical eca and Pfzer being the biggest proponents of the R&D R&D for neglected diseases led by African institu- cuts [10–14]. tions to develop capacities and centres of research Tis paper summarizes the current situation of open excellence there [20]. innovation in the pharmaceutical sector. It describes the • Te Medicines for Malaria Venture (MMV, https concepts and models of opening up pharma R&D, and ://www.mmv.org) was established in 1999 by a few it attempts to address the questions regarding why big European governments together with the World pharma has not yet fully embraced the diferent ideas Bank to reduce the disease burden of Malaria infec- of open innovation and what measures would help to tions [21]. Since then, the programme has gained increase R&D productivity and efciency. more facilitators and received total funding of roughly USD 1 billion by 2016. Te main sponsor is Open source and crowdsourcing to access the Bill and Melinda Gates Foundation, with a 54.7% knowledge of the masses share. Partners form the industry include Novartis, Open source innovation has been successfully applied in Sanof, Merck Serono and Takeda. Te achievements the software industry. Tis radical open model of soft- are enormous. Several hundred million treatments ware development allows anyone to participate, network were provided to children; 18,000 healthcare workers in the product’s development and then share the results. were trained to administer malaria medication; and Rewards for participants are mostly non-monetary but 19 drug candidates have been nominated for clini- are related to recognition and participation, such as the cal development since 1999. Since 2010, the MMV presentation of expertise, the satisfaction by working moved 17 candidates into preclinical development, of on an honourable project, the acquisition of new skills, which 13 are still active [74]. or peer recognition. Around the time when internet • Te Global Alliance for Tuberculosis Drug Develop- became a commodity, the players in the pharmaceuti- ment (TB Alliance, https ://www.tball iance .org) is cal sector became more connected, and in turn, it was an initiative of governmental and non-governmen- possible for R&D organizations to become more decen- tal organizations. It was started in 2000 to discover tralized. Tis development allowed pharmaceutical com- and develop tuberculosis drugs. Today, the TB Alli- panies to more easily access knowledge and ideas from ance manages the largest pipeline of new TB drugs, the outside, promote innovation, use the mass of external including six new products that are in clinical devel- experts to solve problems and to develop technologies opment phases. Several pharmaceutical companies,
Load more

Recommended publications
  • Making Grants to Solve Social and Environmental Problems at Home and Around the World
    Making grants to solve social and environmental problems at home and around the world THE WILLIAM AND FLORA HEWLETT FOUNDATION 2008 Annual Report Forms of Philanthropic Support: The Centrality of Alignment* Paul Brest Nonprofit organizations are the core of civil society. Vibrant organizations require unrestricted capital and need excellent leaders with considerable autonomy to develop and implement their plans. But these organizations and their leaders also depend on funders, who have their own passions, goals, and ideas. How are the interests of donors and nonprofits reconciled in the philanthropic world? Some funders use the power of their purses to resolve the tension in a lopsided way that satisfies their egos but ultimately disserves society. They make small, short-term grants focused on narrowly defined concerns. They require organizations to jump through hoops during the application process, and then micromanage grantees’ activities. In fact, unrestricted, general operating support for organizations accounts for only about 19 percent of all foundation grant dollars.1 Concerned with the pervasive undercapitalization of nonprofit organizations, Independent Sector, Grantmakers for Effective Organizations, and the Nonprofit Finance Fund have strongly advocated that funders provide multi-year, renewable general support.2 At the same time, a small but increasing number of venture philanthropists are providing successful nonprofits the funds necessary to expand.3 Most venture philanthropists support organizations that provide services— education, after-school programs, visits by nurse practitioners. But general support is equally valuable for organizations engaged in research and advocacy, ranging from universities and think tanks to environmental organizations. For all of the value of general support, however, there are often good reasons to fund specific projects.
    [Show full text]
  • Open Content Licensing: Cultivating the Creative Commons
    Open Content Licensing: Cultivating the Creative Commons Principal Editor Professor Brian Fitzgerald Head of School of Law, Queensland University of Technology, Australia With the assistance of Jessica Coates and Suzanne Lewis Sydney Unversity Press Published in Sydney by Sydney University Press University of Sydney NSW 2006 AUSTRALIA Publication date: March 2007 The material in this publication is based on papers presented at the Open Content Licensing: Cultivating the Creative Commons conference held by the Queensland University of Technology (http://www.qut.edu.au) in Brisbane, Australia in January 2005. This publication is an output of the ARC Centre of Excellence for Creative Industries and Innovation (http://www.cci.edu.au), Queensland University of Technology. Unless otherwise stated, the law and services represented in these papers are discussed as they existed in February 2005. ISBN 10 1-920898-51-4 ISBN 13 978-1-920898-51-9 This work is licensed under an Australian Creative Commons Attribution- NonCommercial-NoDerivs 2.5 License available at http://creativecommons.org/licenses/by-nc-nd/2.5/au/. For more information contact Professor Brian Fitzgerald, Faculty of Law, Queensland University of Technology. List of Contributors Richard Neville Professor Arun Sharma Mark Fallu Professor Barry Conyngham AM Greg Lane Professor Brian Fitzgerald Nic Suzor Professor Lawrence Lessig Professor Richard Jones Professor Greg Hearn Professor John Quiggin Dr David Rooney Neeru Paharia Michael Lavarch Stuart Cunningham Dr Terry Cutler Damien O’Brien
    [Show full text]
  • Thick Description of Peer Review Is Required
    Peer Review: Objectivity, Anonymity, Trust A Dissertation Presented by Hans Daniel Ucko to The Graduate School in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy in Philosophy Stony Brook University May 2020 Copyright by Hans Daniel Ucko 2020 Stony Brook University The Graduate School Hans Daniel Ucko We, the dissertation committee for the above candidate for the Doctor of Philosophy degree, hereby recommend acceptance of this dissertation. Robert Crease, Professor Department of Philosophy Anne O’Byrne Associate Professor Department of Philosophy Harvey Cormier Associate Professor Department of Philosophy George Sterman Distinguished Professor Department of Physics and Astronomy This dissertation is accepted by the Graduate School Eric Wertheimer Dean of the Graduate School ii Abstract of the Dissertation Peer Review: Objectivity, Anonymity, Trust by Hans Daniel Ucko Doctor of Philosophy in Philosophy Stony Brook University 2020 Objectivity is a concept that looms large over science. As a society we approve of objective approaches, methods, and attitudes. Objectivity can mean a lot of things: a correspondence with reality, a reliable epistemological process, or an attitude or stance of a scientist. Peer review is an important part of scientific evaluation. Results do not count as science until they are made public, or published. The means by which scientific manuscripts are found to be suitable for publication is peer review, in which usually an editor consults one or more referees to ask for a judgment on the scientific work by an author or authors. These referees are asked to be representatives of a community, that is, they are asked for an objective evaluation not only from their standpoint but instead standing in for an entire community.
    [Show full text]
  • Open Gaming License, Version 1.0A
    LEGAL INFORMATION Permission to copy, modify and distribute the files collectively known as the System Reference Document (“SRD”) is granted solely through the use of the Open Gaming License, Version 1.0a. This material is being released using the Open Gaming License Version 1.0a and you should read and understand the terms of that license before using this material. The text of the Open Gaming License itself is not Open Game Content. Instructions on using the License are provided within the License itself. The following items are designated Product Identity, as defined in Section 1(e) of the Open Game License Version 1.0a, and are subject to the conditions set forth in Section 7 of the OGL, and are not Open Content: Dungeons & Dragons, D&D, Dungeon Master, Monster Manual, d20 System, Wizards of the Coast, d20 (when used as a trademark), Forgotten Realms, Faerûn, character names (including those used in the names of spells or items), places, Red Wizard of Thay, Heroic Domains of Ysgard, Ever-Changing Chaos of Limbo, Windswept Depths of Pandemonium, Infinite Layers of the Abyss, Tarterian Depths of Carceri, Gray Waste of Hades, Bleak Eternity of Gehenna, Nine Hells of Baator, Infernal Battlefield of Acheron, Clockwork Nirvana of Mechanus, Peaceable Kingdoms of Arcadia, Seven Mounting Heavens of Celestia, Twin Paradises of Bytopia, Blessed Fields of Elysium, Wilderness of the Beastlands, Olympian Glades of Arborea, Concordant Domain of the Outlands, Sigil, Lady of Pain, Book of Exalted Deeds, Book of Vile Darkness, beholder, gauth, carrion crawler, tanar’ri, baatezu, displacer beast, githyanki, githzerai, mind flayer, illithid, umber hulk, yuan-ti.
    [Show full text]
  • This Material Is Covered by the Open Gaming License
    LEGAL INFORMATION Permission to copy, modify and distribute the files collectively known as the System Reference Document (“SRD”) is granted solely through the use of the Open Gaming License, Version 1.0a. This material is being released using the Open Gaming License Version 1.0a and you should read and understand the terms of that license before using this material. The text of the Open Gaming License itself is not Open Game Content. Instructions on using the License are provided within the License itself. The following items are designated Product Identity, as defined in Section 1(e) of the Open Game License Version 1.0a, and are subject to the conditions set forth in Section 7 of the OGL, and are not Open Content: Dungeons & Dragons, D&D, Dungeon Master, Monster Manual, d20 System, Wizards of the Coast, d20 (when used as a trademark), Forgotten Realms, Faerûn, character names (including those used in the names of spells or items), places, Red Wizard of Thay, Heroic Domains of Ysgard, Ever-Changing Chaos of Limbo, Windswept Depths of Pandemonium, Infinite Layers of the Abyss, Tarterian Depths of Carceri, Gray Waste of Hades, Bleak Eternity of Gehenna, Nine Hells of Baator, Infernal Battlefield of Acheron, Clockwork Nirvana of Mechanus, Peaceable Kingdoms of Arcadia, Seven Mounting Heavens of Celestia, Twin Paradises of Bytopia, Blessed Fields of Elysium, Wilderness of the Beastlands, Olympian Glades of Arborea, Concordant Domain of the Outlands, Sigil, Lady of Pain, Book of Exalted Deeds, Book of Vile Darkness, beholder, gauth, carrion crawler, tanar’ri, baatezu, displacer beast, githyanki, githzerai, mind flayer, illithid, umber hulk, yuan-ti.
    [Show full text]
  • Exploring Precision FDA, an Online Platform for Crowdsourcing Genomics Jordan Paradise Loyola University Chicago, School of Law, [email protected]
    Loyola University Chicago, School of Law LAW eCommons Faculty Publications & Other Works 2018 Exploring Precision FDA, an Online Platform for Crowdsourcing Genomics Jordan Paradise Loyola University Chicago, School of Law, [email protected] Follow this and additional works at: https://lawecommons.luc.edu/facpubs Part of the Administrative Law Commons, and the Food and Drug Law Commons Recommended Citation Jordan Paradise, Exploring Precision FDA, an Online Platform for Crowdsourcing Genomics, 58 Jurimetrics J. 267-282 (2018) This Article is brought to you for free and open access by LAW eCommons. It has been accepted for inclusion in Faculty Publications & Other Works by an authorized administrator of LAW eCommons. For more information, please contact [email protected]. EXPLORING PRECISION FDA, AN ONLINE PLATFORM FOR CROWDSOURCING GENOMICS Jordan Paradise* ABSTRACT: The U.S. Food and Drug Administration has created an online platform for the next generation sequencing community, enabling users to evaluate biomarker in- formation and share resources. This article examines this online platform and offers sev- eral observations about potential legal and regulatory implications. CITATION: Jordan Paradise, Exploring PrecisionFDA, an Online Platform for CrowdsourcingGenomics, 58 JuRIMETRIcS J. 267-282 (2018). Precision medicine is here, with rapid advancements in the technologies, tools, and life-saving products entering the market for the treatment of serious and life-threatening disease. In May 2017, the United States Food and Drug Ad- ministration (FDA) approved the first cancer treatment for solid tumors based on a genetic biomarker rather than the tissue of origin.1 One month later, the agency approved a companion diagnostic panel that uses next generation se- quencing (NGS) to simultaneously screen a genetic sample for 23 cancer genes, three of which have FDA-approved therapies for non-small cell lung cancer.2 *Georgia Reithal Professor of Law, Loyola University Chicago School of Law.
    [Show full text]
  • The Future Role of HPC in Medical Product Decision Making
    The Future Role of HPC in Medical Product Decision Making LLNL-TR-690736 This document was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor Lawrence Livermore National Security, LLC, nor any of their employees makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or Lawrence Livermore National Security, LLC. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or Lawrence Livermore National Security, LLC, and shall not be used for advertising or product endorsement purposes. This work performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344. 1 Summary Report on a Workshop on the Future Role of High Performance Computing in Medical Product Decision Making Abstract On September 10, 2015, Lawrence Livermore National Laboratory’s Center for Global Security Research1 and High Performance Computing Innovation Center2 hosted a workshop in Silver Spring, Maryland, on the “Future Role of High Performance Computing (HPC) in Medical Product Decision Making.” Stakeholders from academia, industry, national laboratories and government agencies attended and discussed the role of HPC in making regulatory decisions.
    [Show full text]
  • Legal Framework for E-Research: Realising the Potential, Fitzgerald, Brian F., Eds
    QUT Digital Repository: http://eprints.qut.edu.au/ (2008) Legal Framework for E-Research: Realising the Potential, Fitzgerald, Brian F., Eds. Sydney University Press. © Copyright 2008 Sydney University Press (Collection) / Individual authors (Papers) This work (with the exception of Chapter 2: The Fifth Dimension and Chapter 9: NIH Data and Resource Sharing, Data Release and Intellectual Property Policies for Genomics Community Resource Projects) is licensed under an Australian Creative Commons 'By Attribution', 'Non Commercial', 'No Derivative Works.' 2.5 Licence <http://creativecommons.org/licenses/by-nc-nd/2.5/au/>. See http://creativecommons.org.au/licences for more details. Chapter 2: The Fifth Dimension Licence Information Where copyright subsists in this chapter, which is a United States Government Work under s 105 of the U.S. Copyright Act, the work is licensed under a United States Creative Commons 'By Attribution' 3.0 License <http://creativecommons.org/licenses/by/3.0/us/>. Chapter 9: NIH Data and Resource Sharing, Data Release and Intellectual Property Policies for Genomics Community Resource Projects Licence Information Where copyright subsists in this chapter, which is a United States Government Work under s 105 of the U.S. Copyright Act, the work is licensed under a United States Creative Commons 'By Attribution' 3.0 License <http://creativecommons.org/licenses/by/3.0/us/>. LEGAL FRAMEWORK FOR e-RESEARCH: REALISING THE POTENTIAL EDITED BY BRIAN FITZGERALD BA (Griff), LLB (Hons) (QUT), BCL (Oxon), LLM (Harv), PhD (Griff)
    [Show full text]
  • 1 Niva Elkin-Koren* Creative Commons Is a Non-Profit US-Based
    ELKIN-KOREN – DRAFT FEBRUARY 14, 2006 2006 EXPLORING CREATIVE COMMONS 1 EXPLORING CREATIVE COMMONS: A SKEPTICAL VIEW OF A WORTHY PURSUIT THE FUTURE OF THE PUBLIC DOMAIN (P. Bernt Hugenholtz & Lucie Guibault, eds.) Kluwer Law International, forthcoming 2006. Niva Elkin-Koren* I. INTRODUCTION Creative Commons is a non-profit US-based organization, which operates a licensing platform to promote free use of creative works. This innovative initiative is using license agreements for the purpose of strengthening the public domain. The high cost associated with securing a license to use works becomes a serious obstacle for the use and reuse of works created by others. By reducing the legal costs associated with the use of creative content, Creative Commons seeks to make it easier for non-profit players to engage in creative enterprises. The licensing platform aims at lowering the transaction costs of both licensing and acquiring a license for reuse. At the producer's end, authors are offered a licensing scheme for distributing their works for non-commercial use while at the same time safeguarding those works against abuse and misappropriation of their efforts by asserting copyrights. The idea is to facilitate the release of creative works under generous license terms that would make works available for sharing and reuse. At the users' end, the platform is expected to make it easier for prospective creators to identify works, which are available under generous terms, for subsequent creation. Creative Commons advocates the use of copyrights in a rather subversive way that would ultimately change their meaning. Its strategy does not aim at creating a public domain, at least not in the strict legal sense of a regime that is free of any exclusive proprietary rights.
    [Show full text]
  • Open Content - Bestandsaufnahme Und Versuch Einer Definition
    Open Content - Bestandsaufnahme und Versuch einer Definition Diplomarbeit im Fach Informatik Vorgelegt von Andreas John Waldeyerstr. 12, 10247 Berlin Matrikelnummer: 181939 Angefertigt am Institut für Wirtschaftsinformatik und Quantitative Methoden der Technischen Universität Berlin, Fakultät IV (Informatik) Prof. Dr. iur. Bernd Lutterbeck Betreuer: Matthias Bärwolf Abgabe der Arbeit: 14.02.2006 Open Content - Seite 2 I. Zusammenfassung Unter dem Schlagwort Open Content soll der Erfolg von Open-Source-Software auf andere Werkgattungen übertragen werden. Aufwind erhält die Idee des Open Content durch die zunehmende Ausweitung und Befestigung des geistigen Eigentums durch Recht und Architektur, die sich konträr zu den Möglichkeiten digitaler Technologien und weltweiten Networkings verhält. Um Autoren und Künstlern eine klar erkennbare Alternative zu diesen Entwicklungen zu bieten, soll diese Arbeit helfen, den immer noch verschwommenen Begriff Open Content zu schärfen. Anhand einer strukturierten Beobachtung potenzieller Open-Content- Phänomene und eines Vergleiches mit Open-Source-Software wird gezeigt: Hauptthese: Die Prinzipien von Open-Source-Software lassen sich nur dann sinnvoll auf andere Werkgattungen übertragen, wenn die Eigenschaften von OSS nicht formal übernommen, sondern in den Kontext der anderen Werkgattungen übersetzt werden. Auf Basis der gewonnenen Erkenntnisse wird ein Definitionsentwurf im Sinne einer Übersetzung zur Diskussion gestellt. Konsequenz dieser Übersetzung ist u.a., dass Modifizierbarkeit und kommerzielle Nutzung und Verwertung keine konstituierenden Eigenschaften von Open Content sind. Der Definitionsentwurf lautet im Volltext: Definitionsentwurf: Open Content sind schöpferische Werke, wie z.B. Bilder, Musik oder Artikel, mit Ausnahme von Software, die derart veröffentlicht wurden, dass sie ohne die Erlaubnis eines anderen oder durch eine neutral erteilte Erlaubnis an jedermann konsumiert, zitiert und mindestens nichtkommerziell kopiert und verbreitet werden können.
    [Show full text]
  • What Contracts Cannot Do: the Limits of Private Ordering in Facilitating a Creative Commons
    Fordham Law Review Volume 74 Issue 2 Article 3 2005 What Contracts Cannot Do: The Limits of Private Ordering in Facilitating a Creative Commons Niva Elkin-Koren Follow this and additional works at: https://ir.lawnet.fordham.edu/flr Part of the Law Commons Recommended Citation Niva Elkin-Koren, What Contracts Cannot Do: The Limits of Private Ordering in Facilitating a Creative Commons , 74 Fordham L. Rev. 375 (2005). Available at: https://ir.lawnet.fordham.edu/flr/vol74/iss2/3 This Article is brought to you for free and open access by FLASH: The Fordham Law Archive of Scholarship and History. It has been accepted for inclusion in Fordham Law Review by an authorized editor of FLASH: The Fordham Law Archive of Scholarship and History. For more information, please contact [email protected]. What Contracts Cannot Do: The Limits of Private Ordering in Facilitating a Creative Commons Cover Page Footnote Professor, University of Haifa School of Law. I wish to thank Yochai Benkler, Michael Birnhack, Julie Cohen, Rochelle Dryfuss, Kevin Davis, Bernt Hugenholtz, Mathias Klang, Lawrence Lessig, Jessica Litman, Neil Netanel, David Nimmer, Helen Nissenbaum, Gideon Parchomovsky, Eli Salzberger, Anthony Reese, Pamela Samuelson, Katrina Wyman, and Diane Zimmerman for their comments and criticism on an earlier draft. I also thank the participants at the IViR workshop on Commodification of Information, Amsterdam, July 2004, the Colloquium on Information Technology and Society, Information Law Institute, NYU School of Law and UCLA, and the participants of faculty workshops at the University of Connecticut Law School, Georgetown University Law Center, and NYU School of Law for helpful comments and discussions.
    [Show full text]
  • 4 Tabletop Role-Playing Games
    This is an Accepted Manuscript of a book chapter published by Routledge in Role-Playing Game Studies: Transmedia Foundations on April 4, 2018, available online: https://www.routledge.com/Role-Playing-Game-Studies-Transmedia- Foundations/Deterding-Zagal/p/book/9781138638907 Please cite as: William J. White; Jonne Arjoranta; Michael Hitchens; Jon Peterson; Evan Torner; Jonathan Walton (2018). Tabletop Role-Playing Games. In Zagal, José P. and Deterding, S. (eds.), Role-Playing Game Studies: Transmedia Foundations. New York: Routledge, 63-86. 4 Tabletop Role-Playing Games William J. White; Jonne Arjoranta; Michael Hitchens; Jon Peterson; Evan Torner; Jonathan Walton This chapter discusses tabletop role-playing games (TRPGs), sometimes also called “pen and paper” RPGs to distinguish them from their compatriot media, primarily the computer role-playing game (CRPG) and live action role-playing game (LARP). Once some preliminary matters of definition and description are taken care of, the discussion in this chapter proceeds largely along historical lines, presenting TRPGs as (1) originating in the early 1970s with the publication of Dungeons & Dragons and its early offshoots, imitators, and derivations and (2) developing in variety through the 1980s and 1990s as designers sought to emulate different fictional settings and genres as well as explore various game-mechanical approaches before (3) experiencing a period of “mainstream” consolidation and 1 countervailing “indie” experimentation in the first years of the 21st century. It concludes with an attempt to discern the direction of future developments, as the arrival of crowdfunding, print-on-demand, and other Internet-enabled publishing tools change the face of the industry. The historical arc traced here draws in large measure upon two recent histories of the origins of TRPGs, Peterson’s Playing at the World (Peterson 2012) and Appelcline’s multi-volume Designers and Dragons (Appelcline 2013).
    [Show full text]